Literature DB >> 30521628

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.

Andrzej Lange, Emilia Jaskula, Janusz Lange, Grzegorz Dworacki, Dorota Nowak, Aleksandra Simiczyjew, Monika Mordak-Domagala, Mariola Sedzimirska.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0190525.].

Entities:  

Year:  2018        PMID： 30521628      PMCID： PMC6283549          DOI： 10.1371/journal.pone.0209108

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


The following information is missing from the Funding section: Publication of this study was supported by Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014–2018.
  1 in total

1.  The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.

Authors:  Andrzej Lange; Emilia Jaskula; Janusz Lange; Grzegorz Dworacki; Dorota Nowak; Aleksandra Simiczyjew; Monika Mordak-Domagala; Mariola Sedzimirska
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.